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It has previously been reported that patients with lymphoma and
other malignant tumours have significantly larger adrenal glands
than normal subjects (Vincent et al, 1994b). This enlargement is
due to hyperplasia rather than metastatic deposits, and is unrelated
to the stage of disease. However, its clinical significance and rela-
tion to adrenocortical function remain undetermined. Two early
studies on adrenocortical function in patients with malignancy
reported conflicting results. One demonstrated diminished urinary
adrenocortical steroid excretion (Dobriner et al, 1950), whilst
another reported increased basal secretion and impaired suppres-
sion following the administration of a single dose of dexametha-
sone (Bishop and Ross, 1971). However, in the latter study, the
majority of patients had an oat cell bronchogenic carcinoma and
thus it is probable that their adrenocortical overactivity was due to
ectopic adrenocorticotropic hormone (ACTH) production. This
was unlikely to be responsible for the report of adrenal enlarge-
ment in patients with malignancy by Vincent et al (1994b): not
only did none of the patients have or develop clinical stigmata of
the ectopic ACTH syndrome, but this condition is only rarely
associated with haematological malignancies, which made up a
large number of the studied patients. The aims of the present study
were to elucidate the activity of the hypothalamo–pituitary–
adrenal (HPA) axis in patients with malignancy and to correlate
this with the size of adrenal glands, as measured by computerized
tomography (CT), and to test whether any abnormalities were
likely or not to be due to ectopic ACTH production.
METHODS
Fourteen patients with a variety of malignancies were studied at
their initial presentation before the administration of any
chemotherapy or radiotherapy (Table 1). Patients with renal or
hepatic failure, sepsis, or chronic inflammatory conditions were
excluded and all the patients were ambulant and well; none were
incapacitated by their disease. The study was approved by the
local Ethical Committee and all patients gave written informed
consent. The patients did not have any clinical stigmata of
Cushing’s syndrome and had not previously received glucocorti-
coids. After resting in a supine position for 30 min, a fasting serum
blood sample was taken at 09:00 h (2 + 0). Each patient then
received oral dexamethasone (0.5 mg 6-hourly for 48 h), and a
further serum 09:00 h cortisol measurement was obtained after the
last dose (2 + 48). Normally, serum cortisol levels after 48 h of
dexamethasone (2 mg day–1) are < 50 nmol l–1.
A corticotrophin releasing hormone (CRH) stimulation test was
performed in six patients on the day prior to the administration of
the first dose of dexamethasone. After fasting from midnight, an
intravenous cannula was inserted and the patient rested in a supine
position for 30 min. At 09:00 h, 100 mg of human CRH were
administered and serum cortisol measurements taken 15 min
before, and every 15 min afterwards for 2 h. In normal subjects,
the maximum cortisol level after hCRH is 700 nmol l–1 (Trainer
et al, 1995).
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Summary The aim of this study was to further elucidate the activity of the hypothalamo–pituitary–adrenal (HPA) axis in patients with
malignancy and to correlate this with the size of the adrenal glands. Fourteen patients with a variety of malignancies were studied prior to
receiving cytotoxic chemotherapy. During routine staging computerized tomographic (CT) scans, the size of the body, medial and lateral limbs
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malignancy had significantly larger adrenal glands than patients without malignancy; those with non-haematological malignancies had larger
glands than patients with haematological malignancies. Following dexamethasone to suppress circulating cortisol levels, nine patients (64%)
demonstrated abnormal resistance with cortisol levels > 50 nmol l–1: mean value 294 nmol l–1 (range 67–1147). Those patients who failed to
suppress after dexamethasone had significantly larger adrenal glands than those that did suppress and tended to have non-haematological
malignancies. ACTH levels were undetectable or low in three patients in whom it was measured and who did not suppress with
dexamethasone. Following CRH, the cortisol levels were highest (823 and 853 nmol l–1) in two of these patients. Malignancy is associated
with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to
ectopic ACTH secretion. This disturbance of the normal control of the HPA axis is unexplained and its functional significance remains
uncertain.
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assay (RIA) with a minimum detectable concentration set at
50 nmol l–1 (inter-assay and intra-assay variation < 10%). A simul-
taneous plasma ACTH measurement was performed in six patients
using an in-house RIA with a minimum detectable concentration
of 10 pg ml–1 (inter-assay and intra-assay variation < 10%).
CT scans were obtained as part of each patient’s clinical staging
using a GE 9800 Advantage system with standard abdominal
window settings (window level 40, width 400). Contiguous
10-mm thick images were obtained and the best images showing
each part of the adrenal gland were selected independently by two
observers (SAS and RR) in a blinded manner. Using the standard
GE 9800 measurement function, a cursor was deposited on the
margins of the adrenal gland and measurements obtained. The
measurements recorded were:
1. Maximum width of the gland: defined as the maximum width
perpendicular to the long axis of the body of the gland, at the
junction of the adrenal limbs and the body.
2. Width of the adrenal limbs: defined as the maximum width
(thickness) of the medial and lateral limbs of the gland perpen-
dicular to the long axis of the limb.
The measurements were compared to our previously established
normal range for patients without malignancy or inflammatory
conditions (Vincent et al, 1994a). The mean coefficient of varia-
tion for the inter-observer error of each measurement was
5.5–11.4%. In addition, images of the liver were visualized in each
patient and the presence of hepatic metastasis excluded.
Statistics
Student’s t-test was used for comparisons of adrenal size between
all the patients with malignant disease and normal controls; the
Mann–Whitney test was used for comparison of adrenal size
between patients with malignancy. A P-value of < 0.05 was taken
as indicating statistical significance.
RESULTS
The average measurements for the right and left adrenal glands
and their comparison with normal values are shown in Table 2.
Both adrenal glands were identified in all patients, but not all
measurements could be made in every patient because of a paucity
of retroperitoneal fat and/or contiguity with adjacent structures in
some. The right lateral limb was not measured in three patients,
the right medial in a further patient and the left lateral in an addi-
tional single patient. Patients with malignancy had highly signifi-
cant enlargement of all measures of their adrenal glands compared
to normal patients (Figure 1; Table 2).
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Table 1 The clinical details of the patients studied
Patients Sex Age Diagnosis Stage
1 F 39 Nodular sclerosing HD I A
2 M 27 Nodular sclerosing HD I A
3 M 72 High grade B-cell NHL II B
4 M 45 High grade T-cell NHL II E
5 M 73 High grade B-cell NHL II A
6 M 26 Nodular sclerosing HD III A
7 F 61 Low grade B-cell NHL IV A
8 M 75 Low grade B-cell NHL IV A
9 M 85 Rectal carcinoma
10 M 85 Metastatic
adenocarcinoma
(unknown primary)
11 M Oesophageal carcinoma
12 M 64 Carcinomatosis
(unknown primary)
13 M 76 Renal carcinoma
14 F 72 Pancreatic carcinoma
HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma.
B
A
Figure 1 CT images of normal adrenal glands (top; white arrows) and in a
patient with malignancy (bottom; white arrows) showing diffuse enlargementPatients with non-haematological malignancies had signifi-
cantly larger glands compared to patients with haematological
malignancies (right body P < 0.005; left body P < 0.03; right
lateral limb P < 0.01; right medial limb P < 0.05) and had signifi-
cantly higher cortisol levels after administration of dexamethasone
(P < 0.002). There was no relationship between the adrenal size
and stage of haematological disease.
For all patients the range of serum cortisol values before
dexamethasone was 242–983 nmol l–1 (median 545 nmol l–1) and
after its administration < 50–1147 nmol l–1 (median 98 nmol l–1)
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Table 2 The mean (± s.d.) measurements (mm) of the body, medial and lateral limbs of 14 patients with
malignancy compared to normal controls
Right Left
Body Medial Lateral Body Medial Lateral
limb limb limb limb
Patients with 7.6 (2.9) 5.5 (1.7) 4.8 (1.1) 9.4 (2.7) 6.3 (1.6) 6.8 (2.1)
malignancy
Normal control 6.1 (2) 2.8 (0.8) 2.8 (0.6) 7.9 (2.1) 3.3 (0.9) 3.0 (1)
subjects
P-value < 0.02 < 0.0001 < 0.0001 < 0.02 < 0.0001 < 0.0001
Table 3 The serum cortisol nmol l–1 and plasma ACTH pgml–1 values and size (mm) of the body, medial and lateral limbs of the
adrenal glands in patients with a variety of malignancies, before and after a 48-h low-dose dexamethasone suppression test
Patient Cortisol Cortisol ACTH ACTH Right body Right Right Left body Left Left
2 + 0 2 + 48 2 + 0 2 + 48 medial lateral medial lateral
limb limb limb limb
1 417 < 50 17 < 10 5 4 5 7 4 5
2 390 < 50 15 < 10 7 4 5 6 5 5
3 814 110 NR NR 8 5 4 11 8 10
4 928 98 < 10 < 10 4 6 NV 8 6 6
5 242 < 50 14 < 10 3 NV 3 5 4 4
6 322 < 50 NR NR 5 5 4 8 6 4
7 740 < 50 NR NR 9 4 3 10 6 6
8 525 67 29 11 5 4 5 9 NV 7
9 588 182 NR NR 12 7 NV 8 7 7
10 545 222 NR NR 8 9 6 14 8 9
11 983 1147 NR NR 11 7 6 10 9 8
12 616 492 NR NR 9 4.5 6 10 6 8
13 449 101 20 13 9 4 NV 12 5 5
14 598 232 NR NR 12 8 6 14 8 11
NR, not recorded; NV, not visualized.
Table 4 The mean (± s.e.m.) measurements (mm) of the body, medial and lateral limbs of the adrenal glands in
patients with malignancy who failed to suppress serum cortisol levels to < 50 nmol l–1 after a 48-h low-dose
dexamethasone suppression test compared to those patients who did suppress
Right Left
Body Medial Lateral Body Medial Lateral
limb limb limb limb
Non-suppression 8.7 (2.8) 6.1 (1.8) 5.5 (0.8) 10.7 (2.3) 7.1 (1.4) 7.9 (1.9)
Suppression 5.8 (2.2) 4.2 (0.5) 4.0 (1) 7.2 (1.9) 5.0 (1) 4.8 (0.8)
P-value NS NS 0.03 0.02 0.02 0.01
NS, not significant.respectively (Table 3). Following dexamethasone, nine patients
(64%) had cortisol levels above 50 nmol l–1 reflecting resistance to
suppression: mean value 294 nmol l–1, range 67–1147. The 2+48
ACTH levels in the three of these in whom it was measured were
< 10, 11 and 13 pg ml–1; it was < 10 pg ml–1 in three other patients
in whom it was measured, each of whom had cortisol levels
< 50 nmol l–1 after dexamethasone. Those patients who failed to
suppress circulating cortisol after dexamethasone had significantly
larger adrenal glands compared to those who did suppress
(Table 4).
The maximum cortisol level following CRH ranged from 481 to
853 nmol l–1 (median 616) and the percentage increment from –3
to 46% (median 32%). The maximum cortisol levels after CRH
were highest (823 and 853 nmol l–1) in two patients who failed to
suppress with dexamethasone.
DISCUSSION
This study has demonstrated that patients with a variety of malig-
nancies have significantly enlarged adrenal glands as compared to
normal patients. This is in accordance with our previous findings
in a different group of patients, but who had a similar variety of
malignant disease (Vincent et al, 1994b). However, in that study,
no attempt was made to assess the functional activity of the
adrenal glands and to correlate it with the adrenal size. These
results have shown that not only is malignancy associated with
elevated levels of cortisol that are often resistant to suppression
with dexamethasone, but that such resistance is associated with
larger adrenal glands. That this enlargement is not due to
metastatic deposits is indicated by the diffuse nature of the
enlargement without any focal nodules, the lack of any difference
in size of the adrenal glands between patients with early or
advanced disease and the presence of adrenal enlargement in
patients with a wide variety of tumours, including lymphoma,
which involves the adrenals only rarely. In addition, metastatic
enlargement would not be expected to result in hyperfunctioning
of the gland. Although we cannot definitely exclude microscopic
metastases as the cause for the enlargement, such an occurrence
would not be expected to result in diffuse enlargement.
These findings of increased adrenocortical activity concur with
those of an earlier study by Bishop and Ross (1971). They studied
patients with surgically inoperable and metastatic cancer, particu-
larly those with oat cell bronchial carcinoma. Although there was
no significant difference in the 09:00 h plasma 11-hydroxycorti-
coid (mainly cortisol) concentrations between normal patients and
those with either oat cell carcinoma or other tumours, both groups
of patients with malignancy had significantly elevated midnight
steroid values and exhibited less suppression following the admin-
istration of a single 2 mg dose of dexamethasone. However, the
patients in this study differed from those reported above, not only
in the more advanced nature of their disease, but also in that it is
probable that most if not all of their adrenocortical hyperfunction
was due to ectopic ACTH production, a common feature of
bronchogenic oat cell carcinomas. Such ectopic secretion by the
tumours is unlikely to be responsible for our findings. The
maximum level of ACTH, in the six patients in whom it was
measured (three of whom failed to suppress after dexamethasone),
before and after dexamethasone was 29 pg ml–1 and 13 pg ml–1
respectively. These levels are lower than those recognized to be
associated with ectopic production of ACTH, characteristically
greater than 200 pg ml–1 (Besser and Landon, 1968; Ratcliffe et al,
1972; Pullan et al, 1980; Howlett et al, 1986) and suggest an alter-
native pathogenesis for the hyperplasia and resistance to dexa-
methasone. An ectopic source of ACTH is also discounted by the
rarity of this syndrome being recorded with haematological malig-
nancies which accounted for the majority of our patients. The data
from the CRH tests also suggests an ectopic source of ACTH is
less likely. Apart from one patient who suppressed with dexa-
methasone and who had a flat response to CRH, the remaining
patients had a percentage rise above basal cortisol values of
between 26% and 46%. This is greater than the flat response that is
characteristic of patients with Cushing’s syndrome due to ectopic
ACTH (Grossman et al, 1988). The responses to CRH exhibited
by our patients also exclude autonomous adrenal functioning, as
such patients exhibit a flat response to this peptide (Grossman et
al, 1988). Thus, the combination of low levels of ACTH and the
normal or exaggerated cortisol responses to CRH suggest the
action of (i) either an alternative non-ACTH-mediated stimulant
acting predominantly independently on the adrenals or synergisti-
cally on the adrenal response to ACTH, or (ii) acquired resistance
to dexamethasone at the pituitary and/or adrenal level. One patho-
genic mechanism might relate to perturbations in the homeostatic
interplay between the HPA axis and the immune system, in the
form of cytokines (Jenkins and Grossman, 1997). It has been
clearly established that interleukins (ILs) 1a, IL-1b, IL-6 and
IL-2 are all able to exert a direct stimulatory effect on adrenocor-
tical cortisol secretion (Roh et al, 1987; Whitcomb et al, 1988;
Salas et al, 1990; Tominaga et al, 1991; O’Connell et al, 1994),
with the stimulatory effects of IL-1a and IL-1b being suggested to
be mediated via prostaglandins (PGD2, PGF2 and PGE2) (Winter et
al, 1990; Tominaga et al, 1991). Furthermore, IL-6 has been
shown to act synergistically with physiological concentrations of
ACTH in stimulating cortisol secretion (Salas et al, 1990).
Conversely, there is increasing evidence that inflammatory condi-
tions which favour the release of cytokines are associated with
localized resistance to glucocorticoids and antagonism to their
suppressive effects, perhaps by increasing the expression of the
non-ligand-binding  b-isoform of the glucocorticoid receptor
(de Castro et al, 1996; Lamberts et al, 1996). A number of these
cytokines, including g-interferon and tumour necrosis factor-a,
may be secreted by tumours (Merz et al, 1991) and indeed the
secretion of IL-6 has recently been shown to correlate with disease
activity and to be associated with adverse prognostic features
(Seymour et al, 1995). Furthermore, the experimental in vivo
transplantation of lymphoma cells has been shown to markedly
elevate glucocorticoid levels, an effect that can be mirrored by the
transference of ascitic fluid from the lymphoma-bearing animal
(Normann et al, 1988a, 1988b).
Whatever the precise mechanism underlying both the adrenal
enlargement and disturbed pituitary–adrenal regulation, the ques-
tion arises as to its functional significance. The development of a
malignancy might result in increased cytokine levels either via
activation of the immune system due to the associated antigenic
changes or from direct secretion by the tumour. Resultant inter-
ference with the HPA axis, perhaps via cytokine-mediated local-
ized resistance to glucocorticoids might aid tumour growth by
minimizing their immunosuppressive effects. Such a hypothesis is
supported by the clinical benefits of high-dose glucocorticoid
therapy as an effective constituent of the treatment of lymphoma;
although, conversely, patients with ectopic ACTH resulting from
oat cell carcinomas have a worse prognosis compared to non-
ACTH secretors (Hymes and Doe, 1962; Dimopoulos et al, 1992;
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these findings awaits prospective longitudinal studies comparing
adrenal size and function with clinical outcome. Until these issues
are resolved, a radiological report of diffuse bilateral adrenal gland
enlargement in a patient with a known carcinoma and in the
absence of any clinical stigmata of Cushing’s syndrome, probably
does not required detailed endocrinological investigation.
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